Marcus Bertilson
Known title: Chief Operating OfficerCIK: 0002017581
Associated companies
Transaction History
| WEAV | ▼ Sell | Tax Withholding | 8,762 | $64K | 9/15/2026 | View on chart |
| WEAV | ▼ Sell | Tax Withholding | 11,782 | $64K | 6/15/2026 | View on chart |
| WEAV | ▲ Buy | Grant | 300,000 | $0 | 3/26/2026 | View on chart |
| WEAV | ▼ Sell | Tax Withholding | 19,849 | $97K | 3/13/2026 | View on chart |
| WEAV | ▲ Buy | Grant | 150,000 | $0 | 12/16/2025 | View on chart |
| WEAV | ▼ Sell | Tax Withholding | 13,705 | $93K | 12/15/2025 | View on chart |
| WEAV | ▼ Sell | Open Market | 13,836 | $107K | 9/16/2025 | View on chart |
| WEAV | ▼ Sell | Open Market | 11,409 | $97K | 6/17/2025 | View on chart |
| WEAV | ▲ Buy | Grant | 115,000 | $0 | 3/24/2025 | View on chart |
| WEAV | ▼ Sell | Open Market | 27,599 | $313K | 3/19/2025 | View on chart |
| WEAV | ▼ Sell | Tax Withholding | 9,147 | $141K | 12/13/2024 | View on chart |
| WEAV | ▼ Sell | Open Market | 45,000 | $604K | 11/19/2024 | View on chart |
| WEAV | ▼ Sell | Tax Withholding | 7,434 | $79K | 9/13/2024 | View on chart |
| WEAV | ▼ Sell | Open Market | 15,000 | $160K | 9/5/2024 | View on chart |
| WEAV | ▼ Sell | Tax Withholding | 24,165 | $217K | 6/14/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Weave Clears Antitrust Review, Ranks No. 1 in G2 Report
Weave Communications has cleared the HSR antitrust review, allowing the Francisco Partners deal to proceed with an expected close in Q4 2026. The company also secured the top spot in G2's Fall 2026 Patient Relationship Management Grid Report. These developments highlight regulatory progress and industry recognition for the firm.
Weave Clears Antitrust Review, Ranks No. 1 in G2 Report. Weave Communications has cleared the HSR antitrust review, allowing the Francisco Partners deal to proceed with an expected close in Q4 2026. The company also secured the top spot in G2's Fall 2026 Patient Relationship Management Grid Report. These developments highlight regulatory progress and industry recognition for the firm.